Does The *ST In The Securities And Medical Health Deviate From The Draft Reorganization Plan?

In February 26th, *ST was down to 1.54 yuan and the latest total market value was 6 billion 560 million. It announced that it signed the strategic cooperation framework agreement with Kang Ming Bai, and jointly promoted the development of the platform for "Mebs-lg" (antibody editing of the bispecific antibody) platform, and chose to go to the CDMO platform in China. Referring to the Shenzhen Stock Exchange, the Shenzhen Stock Exchange asked for the implementation of securities investment and medical health field in line with the business plan specified in the draft plan.

The court's ruling on the draft reorganization plan shows that the short term business plan for *ST's mid duty redevelopment (2020 -2021) is "around the control of the supply of raw wool and the trade in cashmere related products". The middle and long term business plan (after 2022) is that, on the basis of controlling raw materials, the listed companies will start building high-end brands from raw materials, yarns and fabrics, so as to expand their business scale. And thickening the business purpose of operating profits.

But recently, *ST Zhong Rong has begun to set foot in the field of securities investment and medical health, and intends to open cross-border businesses.

According to the February 18th announcement, the company intends to invest in securities with a total value of not more than 600 million yuan, including investment in new shares or purchase, securities repurchase, stock investment and funds. We are planning to set up Beijing Yan Han technology investment management partnership with Hunan crown Cci Capital Ltd. The company intends to invest 200 million as a limited partner, and Yan Han will invest in the field of bio pharmaceuticals, aerospace, military technology and other fields in the future.

On February 26th, it announced that it signed the strategic cooperation framework agreement with Kang Ming Bai on the 23 day, and jointly promoted the development of the platform for "Mebs-lg" (antibody editing of the bispecific antibody) platform, and chose to go to the CDMO platform in China to provide one-stop technology service for customers to carry out strategic cooperation.

The Shenzhen Stock Exchange asked the company to explain the reasonableness and necessity of developing securities investment, setting up limited partnership and setting foot in the field of medical health, and whether it matches the business plan stipulated in the draft of the company's reorganization plan.